A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
A legfontosabb adatok
- Ki végzi
- AIRNA Corporation
- Hol
- Ausztrália, Egyesült Királyság, Grúzia, Hollandia, Németország, Portugália, Spanyolország, Svédország és Új-Zéland13 helyszín, 9 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 54 fő, tervezett
- Kezdés
- 2026. márc. 17.
- Várható befejezés
- 2029. jan.
- A vizsgálat típusa
- Beavatkozással járó, 10 csoport
- A vizsgált kezelések
- AIR-001 SAD dose level 1
- AIR-001 SAD dose level 2
- AIR-001 SAD dose level 3
- AIR-001 SAD dose level 4
- AIR-001 MD dose level 1
- AIR-001 MD dose level 2
- AIR-001 MD dose level 3
- AIR-001 MD dose level 4
- AIR-001 MD dose level 5
- AIR-001 MD dose level 6
- A regiszteradat frissítve
- 2026. október 23.
Ki vehet részt
- Életkor
- 18 év – 74 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 33 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female participants >18 years and <75 years of age at the time of signing informed consent
- Total serum AAT levels < 11µM (57 mg/dL)
- Pi*ZZ genotype confirmed by DNA sequencing within the SERPINA1 gene with no known co-occurring SERPINA1 null variants
- Spirometry: Forced expiratory volume in 1 second (FEV1) ≥ 40% of predicted
- Non-smoker, including vaping, for at least 6 months prior to screening
- Body mass index between 18-33.0 kg/m²
- Body weight ≥ 45 kg and ≤110 kg
- Willing and able to give written informed consent prior to the initiation of any study procedure by the participant
- Negative beta human chorionic gonadotropin (β-hCG) at enrolment for women of childbearing potential (WOCBP) only
- Participants who are either a WOCBP or male participant who is heterosexually active with a WOCBP must consent to use a highly effective method of contraception from screening visit until at least 4 weeks after the last dose of investigational medicinal product (IMP)
- Willing and able to comply with the study design schedule, all study procedures, and other requirements
Ki nem vehet részt
- Participant has received AAT augmentation therapy within 30 days prior to Screening Visit or plans to receive AAT augmentation therapy at any time during study participation
- Acute respiratory tract infection or clinically-diagnosed chronic obstructive pulmonary disease (COPD) exacerbation that required antibiotic treatment and/or systemic corticosteroids within the 8 weeks prior to dosing
- History of any lung-volume reduction procedure in the 6 months prior to screening
- Current or previous participation in any other clinical study where the participant has received a dose of an IMP within 3 months or 5 half-lives of the IMP, whichever is longest, prior to Screening Visit
- Any previous gene replacement or DNA-editing therapy
- Any previous use of an RNA-based therapeutic (except for AIR-001 or RNA-based vaccines) within the 6 months prior to the Screening Visit or at any time if stopped due to drug-related adverse event
- Use of any new prescription, vaccine, herbal remedy, over-the-counter medication, or supplement, or changes in chronic therapies within the 28 days prior to dosing unless approved by study Medical Monitor
- Known or suspected allergy or intolerance to AIR-001 or its components
- Positive screening test for COVID-19 and/or Influenza
- Lung disease that requires use of continuous oral corticosteroids, continuous supplemental oxygen, day-time ventilatory support, or any participant who is on a lung transplant waiting list
- History of congestive heart failure, serious cardiac arrythmias requiring anti-arrhythmic medications or unexplained black-outs or fainting episodes with a suspected cardiac origin
- Positive screening test or known chronic infection with Hepatitis B, Hepatitis C, or HIV
- Known history of coagulopathy or bleeding diathesis
- History or intolerance to subcutaneous (SC) injection including relevant dermatological conditions affecting standard injection sites
- History or presence of any medical condition, behavioral or psychiatric disorder, or planned surgical procedure or surgical history that may interfere with participation in the study or interpretation of study results, and/or put the participant at significant risk (in the opinion of the investigator) if he/she participates in the study
- History of alcohol or drug abuse within the past three months
- Any of the following screening laboratory abnormalities:; Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) > 3 x upper limit of normal (ULN); Total bilirubin > ULN (note: for participants with documented Gilbert's syndrome and direct bilirubin ≤ ULN , exclusion criterion is total bilirubin is > 2.5 mg/dL); INR > ULN (for participants taking stable doses of anticoagulants, the exclusion criterion is INR > 3.0); Platelet count ≤ 150 k/μL; Estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73m² by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation; Urine Albumin-to-Creatinine Ratio > 300 mg/g; Urine Protein-to-Creatinine Ratio > 500 mg/g
- Prolonged QT interval on electrocardiogram (ECG), defined as QTcF ≥ 450ms (men) or ≥ 470ms (women)
- ECG findings at screening that render measurements of QT interval imprecise
- Laboratory value(s) outside the laboratory reference range that is (are) considered to be clinically significant and may affect the safety, efficacy, PK, or PD assessments or interpretation by the Investigator, at screening
- Female participants who are nursing or lactating
- Liver Fibrosis score > 10 kPa defined by screening liver elastography, historical liver biopsy showing ≥ F3 fibrosis (METAVIR or comparable scoring system), or established diagnosis of hepatic cirrhosis
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 74 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
9 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a Phase 1, open-label, single ascending dose (SAD) and multiple dose (MD) study of AIR-001 in participants with alpha-1 antitrypsin deficiency (AATD) due to PiZZ genotype.
A vizsgálat 10 csoportja
- AIR-001 SAD Cohort 1A vizsgált kezelés
AIR-001 is an RNA-editing oligonucleotide in sterile preservative-free solution administered by subcutaneous (SC) injection as a single dose.
Kezelés: AIR-001 SAD dose level 1
- AIR-001 SAD Cohort 2A vizsgált kezelés
AIR-001 administered by SC injection as a single dose.
Kezelés: AIR-001 SAD dose level 2
- AIR-001 SAD Cohort 3A vizsgált kezelés
AIR-001 administered by SC injection as a single dose.
Kezelés: AIR-001 SAD dose level 3
- AIR-001 SAD Cohort 4A vizsgált kezelés
AIR-001 administered by SC injection, single dose.
Kezelés: AIR-001 SAD dose level 4
- AIR-001 MD Cohort 1A vizsgált kezelés
AIR-001 is an RNA-editing oligonucleotide in sterile preservative-free solution administered by subcutaneous (SC) injection as multiple doses.
Kezelés: AIR-001 MD dose level 1
- AIR-001 MD Cohort 2A vizsgált kezelés
AIR-001 administered by SC injection as multiple doses.
Kezelés: AIR-001 MD dose level 2
- AIR-001 MD Cohort 3A vizsgált kezelés
AIR-001 administered by SC injection as multiple doses.
Kezelés: AIR-001 MD dose level 3
- AIR-001 MD Cohort 4A vizsgált kezelés
AIR-001 administered by SC injection as multiple doses.
Kezelés: AIR-001 MD dose level 4
- AIR-001 MD Cohort 5A vizsgált kezelés
AIR-001 administered by SC injection as multiple doses.
Kezelés: AIR-001 MD dose level 5
- AIR-001 MD Cohort 6A vizsgált kezelés
AIR-001 administered by SC injection as multiple doses.
Kezelés: AIR-001 MD dose level 6
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase 1, Open-Label, Single Ascending Dose and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered AIR-001 in Adults With AATD Due to PiZZ Genotype
- Illeszkedési kérdések
- Forrás: NCT07431112: ki vehet részt
- A regiszteradat frissítve
- 2026. október 23.